Lacerta Therapeutics is a clinical stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases. With unmatched scientific expertise and depth in the development, production, and application of AAV vectors, LacertaTherapeutics is advancing its clinical programs using its proprietary capsid variants and scalable vector manufacturing platform. The experience and accomplishments of the Lacerta Therapeutics founders are unsurpassed in AAV gene therapy. In addition to world-class basic AAV vector development and gene therapy clinical trial expertise, our team brings to bear individuals with novel insight into developing novel, targeted neurological and lysosomal storage disease treatments.

Biotechnology

Therapeutics

Lacerta Therapeutics

Barb Eppler

Venu Talla

John Spence

Megha Mahabole, MS, CTBS

Ryan M Spengler

Shannon Wilson

April Green

Fatima Shaerzadeh

The Research and Development team at Lacerta Therapeutics focuses on advancing innovative gene therapies for central nervous system and lysosomal storage diseases. Leveraging their expertise in adeno-associated virus (AAV) vector technologies, the team collaborates on capsid engineering, bioinformatics, and scientific research to drive the development and optimization of therapeutic candidates, ensuring they are both effective and safe for clinical use.

Research and Development

Leadership Team

Research and Development

About

Team members

Other teams at Lacerta Therapeutics

Leadership Team